Recursion Pharmaceuticals Inc (RXRX)
6.175
-0.74
(-10.64%)
USD |
NASDAQ |
Nov 15, 16:00
6.30
+0.12
(+2.02%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (TTM): 285.57M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 285.57M |
| June 30, 2024 | 280.98M |
| March 31, 2024 | 262.11M |
| December 31, 2023 | 241.23M |
| September 30, 2023 | 215.72M |
| June 30, 2023 | 186.55M |
| March 31, 2023 | 169.93M |
| December 31, 2022 | 155.70M |
| Date | Value |
|---|---|
| September 30, 2022 | 160.01M |
| June 30, 2022 | 152.42M |
| March 31, 2022 | 143.60M |
| December 31, 2021 | 135.27M |
| September 30, 2021 | 107.68M |
| June 30, 2021 | 90.97M |
| March 31, 2021 | 74.59M |
| December 31, 2020 | 63.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
63.32M
Minimum
Dec 2020
285.57M
Maximum
Sep 2024
170.35M
Average
157.85M
Median
Research and Development Expense (TTM) Benchmarks
| Revance Therapeutics Inc | 77.24M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |